HRP20220303T1 - Tekuća formulacija koja sadrži peonol i apocinin - Google Patents
Tekuća formulacija koja sadrži peonol i apocinin Download PDFInfo
- Publication number
- HRP20220303T1 HRP20220303T1 HRP20220303TT HRP20220303T HRP20220303T1 HR P20220303 T1 HRP20220303 T1 HR P20220303T1 HR P20220303T T HRP20220303T T HR P20220303TT HR P20220303 T HRP20220303 T HR P20220303T HR P20220303 T1 HRP20220303 T1 HR P20220303T1
- Authority
- HR
- Croatia
- Prior art keywords
- isomer
- auxiliary agent
- apocynin
- peonol
- formulation
- Prior art date
Links
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 title claims 22
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 title claims 13
- 229930188866 apocynin Natural products 0.000 title claims 10
- 239000012669 liquid formulation Substances 0.000 title claims 6
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 title 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 239000012752 auxiliary agent Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000003827 glycol group Chemical group 0.000 claims 4
- 239000000374 eutectic mixture Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002334 glycols Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (15)
1. Tekuća formulacija, naznačena time što sadrži aktivne spojeve 2-hidroksi-4-metoksiacetofenon (peonol) ili njegov izomer i 4-hidroksi-3-metoksiacetofenon (apocinin) ili njegov izomer, što se težinski omjer između peonola i apocinina kreće od 3:2 do 9:1, gdje tekuća formulacija dodatno sadrži najmanje jedno pomoćno sredstvo, što se težinski omjer između ukupnih aktivnih spojeva i pomoćnog sredstva kreće od 2:3 do 19:1, te što je pomoćno sredstvo glikol ili derivat glikola, polihidroksilni alkohol, ili njegov ester i/ili eter.
2. Formulacija u skladu s patentnim zahtjevom 1, naznačena time što je pomoćno sredstvo glikol, primjerice što je pomoćno sredstvo polietilen-glikol, ili primjerice što je pomoćno sredstvo polietilen-glikol 400.
3. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se težinski omjer između peonola ili njegovog izomera i apocinina ili njegovog izomera kreće od 80:20 do 77,7:22,3.
4. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je težinski omjer između ukupnih aktivnih spojeva i pomoćnog sredstva 64:36.
5. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je formulacija stabilna na sobnoj temperaturi.
6. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je načinjena od eutektične smjese 2-hidroksi-4-metoksiacetofenona (peonola) ili njegovog izomera s 4-hidroksi-3-metoksiacetofenonom (apocininom) ili njegovim izomeri.
7. Tekuća formulacija, naznačena time što je načinjena od eutektične smjese koja sadrži aktivne spojeve peonol ili njegov izomer i apocinin ili njegov izomer, gdje tekuća formulacija dodatno sadrži najmanje jedno pomoćno sredstvo.
8. Formulacija u skladu s patentnim zahtjevom 7, naznačena time što je pomoćno sredstvo glikol ili glikol derivat, polihidroksilni alkohol, ili njegov ester i/ili eter, primjerice što je pomoćno sredstvo glikol, ili primjerice što je pomoćno sredstvo polietilen-glikol, ili primjerice što je pomoćno sredstvo polietilen-glikol 400.
9. Formulacija u skladu s bilo kojim od patentnih zahtjeva 7 do 8, naznačena time što se težinski omjer između ukupnih aktivnih spojeva i pomoćnog sredstva kreće od 2:3 do 19:1, po mogućnosti od 2:3 do 9:1, primjerice što je težinski omjer između ukupnih aktivnih spojeva i pomoćnog sredstva 64:36.
10. Formulacija u skladu s bilo kojim od patentnih zahtjeva 7 do 9, naznačena time što se težinski omjer između peonola ili njegovog izomera i apocinina ili njegovog izomera kreće od 3:2 do 9:1, primjerice što se težinski omjer između peonola ili njegovog izomera i apocinina ili njegovog izomera kreće od 80:20 do 77,7:22,3.
11. Formulacija u skladu s bilo kojim od patentnih zahtjeva 7 do 10, naznačena time što je formulacija stabilna na sobnoj temperaturi.
12. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je namijenjena upotrebi u liječenju upalne bolesti.
13. Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je namijenjena upotrebi u liječenju neurodegenerativne bolesti.
14. Postupak proizvodnje tekuće formulacije koja sadrži aktivne spojeve peonol ili njegov izomer i apocinin ili njegov izomer, naznačen time što se sastoji u (a) pripravi eutektične smjese aktivnih spojeva peonola ili njegovog izomera s apocininom ili njegovim izomerom.
15. Postupak proizvodnje u skladu s patentnim zahtjevom 14, naznačen time što dodatno uključuje (b) dodavanje pomoćnog sredstva (primjerice glikola).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1719464.8A GB2568698A (en) | 2017-11-23 | 2017-11-23 | Formulation |
| PCT/EP2018/082178 WO2019101842A1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| EP18810956.5A EP3713546B1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220303T1 true HRP20220303T1 (hr) | 2022-05-13 |
Family
ID=60950758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220303TT HRP20220303T1 (hr) | 2017-11-23 | 2018-11-22 | Tekuća formulacija koja sadrži peonol i apocinin |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11701325B2 (hr) |
| EP (2) | EP3713546B1 (hr) |
| JP (2) | JP7314157B2 (hr) |
| KR (1) | KR20200090858A (hr) |
| CN (2) | CN111372572B (hr) |
| AU (2) | AU2018371165B2 (hr) |
| CA (1) | CA3082945A1 (hr) |
| CY (1) | CY1124986T1 (hr) |
| DK (1) | DK3713546T3 (hr) |
| ES (1) | ES2906761T3 (hr) |
| GB (1) | GB2568698A (hr) |
| HR (1) | HRP20220303T1 (hr) |
| HU (1) | HUE057595T2 (hr) |
| LT (1) | LT3713546T (hr) |
| MX (2) | MX2020005313A (hr) |
| PL (1) | PL3713546T3 (hr) |
| PT (1) | PT3713546T (hr) |
| RS (1) | RS62923B1 (hr) |
| SI (1) | SI3713546T1 (hr) |
| WO (1) | WO2019101842A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202218160D0 (en) * | 2022-12-02 | 2023-01-18 | Akl Res & Development Ltd | Formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA903759B (en) * | 1989-05-16 | 1991-02-27 | Puetter Medice Chem Pharm | Process for preparing optically active 2-aryl alkanoic acids,in particular 2-aryl propionic acids |
| CN100544708C (zh) * | 2004-08-18 | 2009-09-30 | 上海佰加壹医药有限公司 | 一种丹皮酚软胶囊及其制备方法 |
| GB2424833B (en) * | 2005-04-08 | 2008-12-10 | Nicholas John Larkins | Anti-inflammatory formulation comprising apocyanin and paeonol |
| GB2463080A (en) * | 2008-09-02 | 2010-03-03 | Nicholas John Larkins | Pharmaceutical preparation |
| GB201115757D0 (en) * | 2011-09-12 | 2011-10-26 | Akl Inflammatory Ltd | Formulation for the treatment of benign prostate hyperplasia |
| GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
| GB2547241A (en) * | 2016-02-11 | 2017-08-16 | Akl Res & Dev Ltd | Anti-inflammatory formulation |
-
2017
- 2017-11-23 GB GB1719464.8A patent/GB2568698A/en not_active Withdrawn
-
2018
- 2018-11-22 JP JP2020545869A patent/JP7314157B2/ja active Active
- 2018-11-22 CA CA3082945A patent/CA3082945A1/en active Pending
- 2018-11-22 SI SI201830590T patent/SI3713546T1/sl unknown
- 2018-11-22 PT PT188109565T patent/PT3713546T/pt unknown
- 2018-11-22 HR HRP20220303TT patent/HRP20220303T1/hr unknown
- 2018-11-22 EP EP18810956.5A patent/EP3713546B1/en active Active
- 2018-11-22 EP EP21209333.0A patent/EP4019005A1/en active Pending
- 2018-11-22 AU AU2018371165A patent/AU2018371165B2/en active Active
- 2018-11-22 CN CN201880075175.5A patent/CN111372572B/zh active Active
- 2018-11-22 DK DK18810956.5T patent/DK3713546T3/da active
- 2018-11-22 PL PL18810956T patent/PL3713546T3/pl unknown
- 2018-11-22 MX MX2020005313A patent/MX2020005313A/es unknown
- 2018-11-22 KR KR1020207018001A patent/KR20200090858A/ko active IP Right Grant
- 2018-11-22 ES ES18810956T patent/ES2906761T3/es active Active
- 2018-11-22 HU HUE18810956A patent/HUE057595T2/hu unknown
- 2018-11-22 US US16/765,627 patent/US11701325B2/en active Active
- 2018-11-22 RS RS20220135A patent/RS62923B1/sr unknown
- 2018-11-22 CN CN202310468972.2A patent/CN116999417A/zh active Pending
- 2018-11-22 WO PCT/EP2018/082178 patent/WO2019101842A1/en unknown
- 2018-11-22 LT LTEPPCT/EP2018/082178T patent/LT3713546T/lt unknown
-
2020
- 2020-07-13 MX MX2022008551A patent/MX2022008551A/es unknown
-
2022
- 2022-02-10 CY CY20221100119T patent/CY1124986T1/el unknown
-
2023
- 2023-05-12 JP JP2023079234A patent/JP2023104963A/ja active Pending
- 2023-06-01 US US18/327,202 patent/US20230330017A1/en active Pending
-
2024
- 2024-05-27 AU AU2024203514A patent/AU2024203514A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230330017A1 (en) | 2023-10-19 |
| CN111372572B (zh) | 2023-08-29 |
| GB201719464D0 (en) | 2018-01-10 |
| JP2021504461A (ja) | 2021-02-15 |
| KR20200090858A (ko) | 2020-07-29 |
| WO2019101842A1 (en) | 2019-05-31 |
| EP3713546A1 (en) | 2020-09-30 |
| RS62923B1 (sr) | 2022-03-31 |
| JP2023104963A (ja) | 2023-07-28 |
| HUE057595T2 (hu) | 2022-05-28 |
| JP7314157B2 (ja) | 2023-07-25 |
| PL3713546T3 (pl) | 2022-05-02 |
| CY1124986T1 (el) | 2023-01-05 |
| EP4019005A1 (en) | 2022-06-29 |
| AU2018371165B2 (en) | 2024-02-29 |
| LT3713546T (lt) | 2022-03-10 |
| MX2020005313A (es) | 2020-08-17 |
| CN116999417A (zh) | 2023-11-07 |
| ES2906761T3 (es) | 2022-04-20 |
| US20200297628A1 (en) | 2020-09-24 |
| CN111372572A (zh) | 2020-07-03 |
| AU2018371165A1 (en) | 2020-05-21 |
| EP3713546B1 (en) | 2021-12-08 |
| GB2568698A (en) | 2019-05-29 |
| US11701325B2 (en) | 2023-07-18 |
| PT3713546T (pt) | 2022-02-02 |
| SI3713546T1 (sl) | 2022-04-29 |
| AU2024203514A1 (en) | 2024-06-20 |
| DK3713546T3 (da) | 2022-01-31 |
| MX2022008551A (es) | 2022-08-10 |
| CA3082945A1 (en) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000712A1 (es) | Adyuvantes mejorados para productos agroquímicos | |
| PE20131359A1 (es) | Composiciones que contienen un insecticida de piripiropeno y una base | |
| BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
| AR082222A1 (es) | Composiciones herbicidas sinergicas que contienen aminopiralid, acido 2,4-diclorofenoxiacetico y atrazina | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| CR20170372A (es) | Compuestos de benzoxaborol y usos de los mismos | |
| BR112016002917A2 (pt) | formulação agroquímica, formulação concentrada, e, método para tratamento de vegetação para controlar pestes | |
| UA113656C2 (xx) | Гербіцидна композиція, яка має поліпшену гербіцидну активність | |
| HRP20201354T1 (hr) | Tekuće formulacije levotiroksina | |
| UY36460A (es) | Pirazolpiridinaminas | |
| HRP20220303T1 (hr) | Tekuća formulacija koja sadrži peonol i apocinin | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| CR20160281A (es) | Formulaciones de giberelina con baja cantidad de productos químicos orgánicos volátiles | |
| RU2018111036A (ru) | Композиции, содержащие экстракт эхинацеи и производные соединения линолевой кислоты | |
| WO2011112922A3 (en) | Co-crystals and pharmaceutical formulations comprising the same | |
| WO2016116403A8 (en) | Polyurethaneurea solutions for compositions with active ingredients or fragrances | |
| ECSP18000533A (es) | Una giberelina líquida a concentración alta con bajo nivel de cov | |
| ECSP14026432A (es) | (r)-nifuratel y síntesis de (r) y (s)-nifuratel | |
| AR096338A1 (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles | |
| MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| AR110329A1 (es) | Una formulación plaguicida sólida, estable, auto-dispersable, de baja espuma | |
| AR100001A1 (es) | Composiciones esporicidas clostridium difficile | |
| ECSP19026563A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| CL2021002149A1 (es) | Formulación de afabicin, método para elaborar la misma | |
| JP2023104963A5 (hr) |